Truepill raises US$142mn Series D funding
Since the company’s founding in 2016, Truepill has seen exponential demand for its consumer healthcare platform. When COVID-19 fundamentally disrupted the healthcare industry, the need for digital experiences soared and Truepill’s growth accelerated at an unprecedented rate. Over the last year and a half alone the company has experienced several milestones:
- Debuted two new core services - telehealth and diagnostics - alongside its existing pharmacy service, making Truepill the only platform to deliver all elements of digital healthcare within one platform
- Launched a COVID-19 wellness programme, an end-to-end, customisable solution to enable a safe return to work, travel, school and more
- Launched Virtual Pharmacy, the first-ever white-labeled pharmacy e-commerce platform
- Expanded pharmacy fulfillment capabilities, opening multiple new facilities
- Shipped nearly 10 million prescriptions, processed nearly one million diagnostic tests and facilitated over 50,000 telehealth visits per week (to date)
- Powered programs for the nation's leading health plans, employer groups, D2C health brands and pharmaceutical manufacturers
“When we started Truepill in 2016, we set out to revolutionize the patient experience from the backend and, in the process, created the defining platform for digital consumer healthcare,” said Umar Afridi, CEO and co-founder of Truepill. “No matter what program they’re building, our partners can pick the components they want, tailor a solution to their specific needs and scale up operations as they grow. Our flexible B2B model truly creates limitless possibilities for the future of consumer health, and we’re excited to continue deepening our work within the broader healthcare ecosystem.”
